134 related articles for article (PubMed ID: 37313912)
21. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery.
Kirienko M; Cozzi L; Antunovic L; Lozza L; Fogliata A; Voulaz E; Rossi A; Chiti A; Sollini M
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):207-217. PubMed ID: 28944403
[TBL] [Abstract][Full Text] [Related]
22. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
24. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
25. Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC.
Coroller TP; Agrawal V; Huynh E; Narayan V; Lee SW; Mak RH; Aerts HJWL
J Thorac Oncol; 2017 Mar; 12(3):467-476. PubMed ID: 27903462
[TBL] [Abstract][Full Text] [Related]
26. Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy.
Hayano K; Kulkarni NM; Duda DG; Heist RS; Sahani DV
AJR Am J Roentgenol; 2016 May; 206(5):987-93. PubMed ID: 26934729
[TBL] [Abstract][Full Text] [Related]
27. Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRT.
Huynh E; Coroller TP; Narayan V; Agrawal V; Romano J; Franco I; Parmar C; Hou Y; Mak RH; Aerts HJ
PLoS One; 2017; 12(1):e0169172. PubMed ID: 28046060
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma: CT texture analysis as a predictor of survival after surgical resection.
Brenet Defour L; Mulé S; Tenenhaus A; Piardi T; Sommacale D; Hoeffel C; Thiéfin G
Eur Radiol; 2019 Mar; 29(3):1231-1239. PubMed ID: 30159621
[TBL] [Abstract][Full Text] [Related]
29. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
[TBL] [Abstract][Full Text] [Related]
30. Homology-based radiomic features for prediction of the prognosis of lung cancer based on CT-based radiomics.
Kadoya N; Tanaka S; Kajikawa T; Tanabe S; Abe K; Nakajima Y; Yamamoto T; Takahashi N; Takeda K; Dobashi S; Takeda K; Nakane K; Jingu K
Med Phys; 2020 Jun; 47(5):2197-2205. PubMed ID: 32096876
[TBL] [Abstract][Full Text] [Related]
31. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
[TBL] [Abstract][Full Text] [Related]
32. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
33. CT radiomics-based long-term survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment.
Chen NB; Xiong M; Zhou R; Zhou Y; Qiu B; Luo YF; Zhou S; Chu C; Li QW; Wang B; Jiang HH; Guo JY; Peng KQ; Xie CM; Liu H
Radiat Oncol; 2022 Nov; 17(1):184. PubMed ID: 36384755
[TBL] [Abstract][Full Text] [Related]
34. Radiomics Nomogram for Predicting Locoregional Failure in Locally Advanced Non-small Cell Lung Cancer Treated with Definitive Chemoradiotherapy.
Chen X; Tong X; Qiu Q; Sun F; Yin Y; Gong G; Xing L; Sun X
Acad Radiol; 2022 Feb; 29 Suppl 2():S53-S61. PubMed ID: 33308945
[TBL] [Abstract][Full Text] [Related]
35. Homological radiomics analysis for prognostic prediction in lung cancer patients.
Ninomiya K; Arimura H
Phys Med; 2020 Jan; 69():90-100. PubMed ID: 31855844
[TBL] [Abstract][Full Text] [Related]
36. Non-small cell lung cancer: histopathologic correlates for texture parameters at CT.
Ganeshan B; Goh V; Mandeville HC; Ng QS; Hoskin PJ; Miles KA
Radiology; 2013 Jan; 266(1):326-36. PubMed ID: 23169792
[TBL] [Abstract][Full Text] [Related]
37. Texture analysis of small renal cell carcinomas at MDCT for predicting relevant histologic and protein biomarkers.
Scrima AT; Lubner MG; Abel EJ; Havighurst TC; Shapiro DD; Huang W; Pickhardt PJ
Abdom Radiol (NY); 2019 Jun; 44(6):1999-2008. PubMed ID: 29804215
[TBL] [Abstract][Full Text] [Related]
38. Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy.
Grewal AS; Min EJ; Long Q; Grewal SK; Jain V; Levin WP; Cengel KA; Swisher-McClure S; Aggarwal C; Bauml JM; Singh A; Ciunci C; Cohen RB; Langer C; Feigenberg SJ; Berman AT
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):358-368. PubMed ID: 31654783
[TBL] [Abstract][Full Text] [Related]
39. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
40. Respiration-Averaged CT for Attenuation Correction of PET Images - Impact on PET Texture Features in Non-Small Cell Lung Cancer Patients.
Cheng NM; Fang YH; Tsan DL; Hsu CH; Yen TC
PLoS One; 2016; 11(3):e0150509. PubMed ID: 26930211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
